Wegovy vs. Mounjaro: 8 Important Differences, Backed by Primary Sources
GoodRx broke it down this week — here's what the FDA labels and peer-reviewed trials actually say about these two drugs.
Good — I now have solid primary-source material from the FDA labels for Wegovy, Mounjaro, and Zepbound, plus multiple PubMed studies. Let me write the article.
GoodRx put out a breakdown this week listing eight key differences between Wegovy and Mounjaro — and it's worth unpacking, because these two drugs get lumped together constantly. They're not the same drug. They don't work the same way. And for some people, the differences genuinely matter.
Here's what the primary sources — FDA labels, clinical trials, peer-reviewed journals — actually say.
Difference #1: The Mechanism — One Target vs. Two
This is the foundational difference everything else flows from.
Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics one hormone — glucagon-like peptide-1 — to slow digestion, reduce appetite, and help regulate blood sugar.
Mounjaro (tirzepatide) hits two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). According to the FDA's Mounjaro label, it is classified specifically as a "GIP receptor and GLP-1 receptor agonist." That dual action is why tirzepatide behaves differently — and in trials, often more potently — than semaglutide alone.
Difference #2: What Each Drug Is FDA-Approved For
This trips people up because tirzepatide exists under two brand names depending on the condition being treated.
According to the FDA's Wegovy label, semaglutide is approved for chronic weight management in adults and adolescents aged 12+, for reducing major cardiovascular events in adults with obesity or overweight who have established CV disease, and — under accelerated approval — for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Mounjaro, per its FDA label, is approved specifically for glycemic control in type 2 diabetes in adults and patients aged 10+. It is not the weight-management label. For weight loss, tirzepatide's brand name is Zepbound, which per the Zepbound FDA label is also approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — an indication Wegovy does not currently hold.
Difference #3: What the Head-to-Head Data Shows on Weight Loss
No randomized head-to-head trial comparing the two for weight loss has been published as of this writing. But real-world and network meta-analysis data exist.
A 2024 JAMA Internal Medicine study comparing semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity found tirzepatide was associated with greater weight reduction in a real-world population. A separate 2024 Cureus study on real-world efficacy and safety also reported tirzepatide showed greater weight reduction compared to semaglutide. A 2024 network meta-analysis in Diabetologia comparing subcutaneous tirzepatide vs. semaglutide in type 2 diabetes found tirzepatide associated with greater reductions in HbA1c and body weight.
More weight loss on average does not automatically mean tirzepatide is the right choice for you — tolerability, cost, and your specific health history all factor in.
Difference #4: Cardiovascular Evidence
Wegovy has a cardiovascular outcomes trial behind it. The SELECT trial, published in the New England Journal of Medicine (2023), found semaglutide reduced the risk of major adverse cardiovascular events in adults with obesity or overweight who had established cardiovascular disease but not diabetes. That finding is now baked directly into Wegovy's FDA-approved indications.
Tirzepatide's cardiovascular outcomes data is still maturing. The FDA's Mounjaro and Zepbound labels do not currently carry a comparable cardiovascular risk-reduction indication. If CV protection is a priority for your prescriber, that's a meaningful clinical distinction.
Difference #5: Shared Side Effects — and Where They Diverge
Both drugs share a largely overlapping side effect profile. The Wegovy FDA label lists nausea, diarrhea, vomiting, constipation, and abdominal pain as the most common adverse reactions (≥5%). The Mounjaro label lists the same core five.
Both labels also carry warnings about acute pancreatitis, gallbladder disease, kidney injury from volume depletion, and a boxed warning about thyroid C-cell tumors observed in animal studies. Neither drug is recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2.
One Wegovy-specific note: the FDA label flags hair loss and diabetic retinopathy complications in people with type 2 diabetes. The Zepbound label also lists hair loss and injection site reactions as reported adverse events.
Difference #6: Who Makes Them and What That Means for Access
Wegovy is made by Novo Nordisk. Mounjaro and Zepbound are made by Eli Lilly. Manufacturer matters practically — it affects patient assistance programs, supply chain history, and which pharmacy benefit managers have negotiated coverage. Supply shortages have hit both brands at different times; checking your specific plan's formulary is more useful than assuming either is "easier to get."
Difference #7: Age Approval
Wegovy is approved for adolescents aged 12 and older for weight management. Mounjaro is approved for glycemic control in patients aged 10 and older with type 2 diabetes. Zepbound's weight-management indication is currently for adults only. If you're asking about a younger patient, that distinction matters.
Difference #8: The Oral Option
Wegovy now exists as an oral tablet — the FDA label for Wegovy covers both injection and tablet formulations. Tirzepatide remains injection-only as of this writing. For people with needle aversion, that's a real-world difference worth raising with a prescriber.
What This Means for You
- Mechanism matters. Tirzepatide's dual GIP/GLP-1 action is genuinely different from semaglutide's single-receptor approach, and real-world data suggests greater average weight loss — but "more" isn't always "better for you specifically."
- FDA approvals are not interchangeable. Wegovy has cardiovascular risk-reduction and MASH indications that Mounjaro/Zepbound don't currently share. Zepbound has an OSA indication Wegovy doesn't. These aren't marketing details — they reflect different bodies of clinical evidence.
- Talk to your prescriber about the full picture — your cardiovascular history, diabetes status, needle tolerance, insurance formulary, and weight-loss goals all shape which drug makes sense.
Not medical advice. Talk to your prescriber about your specific situation.
